论文部分内容阅读
肿瘤微环境疗法已成为治疗恶性肿瘤的一个重要新靶点。血管内皮抑素(Endostatin,ES)是目前研究最为透彻的内源性血管生成抑制因子,具有广谱的抗血管形成活性,可以与正常的血管形成相关基因进行作用,且毒副作用低可长期应用。大量研究证实ES可以抑制许多肿
Tumor microenvironmental therapy has become an important new target for the treatment of malignant tumors. Endostatin (ES) is currently the most well studied endogenous angiogenesis inhibitor with broad spectrum of anti-angiogenic activity, which can interact with normal angiogenesis-related genes and has low toxicity and long-term application . Numerous studies have confirmed that ES can inhibit many swollen